eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | hypercalcemia |
| Symptom | C0026764|multiple myeloma |
| Sentences | 6 |
| PubMedID- 21915243 | Interestingly, aminobisphosphonates (abs) which are synthetic compounds commonly used to treat bone disease and hypercalcemia in patients with multiple myeloma, breast or prostate cancer, have been identified also as antigens for γδ t cells, indicating these molecules as immunomodulating factors –. |
| PubMedID- 22073517 | multiple myeloma with hypercalcemia and chloride resistant metabolic alkalosis. |
| PubMedID- 25128013 | Denosumab for the management of hypercalcemia of malignancy in patients with multiple myeloma and renal dysfunction. |
| PubMedID- 24334568 | It is the most common primary bone malignancy, and the extensive osteoclastic bone resorption common in multiple myeloma is associated with hypercalcemia in as many as one-third of patients. |
| PubMedID- 26500541 | hypercalcemia in multiple myeloma may be the result of bone marrow infiltration and release of osteoclast-activating factors by the plasma cells 3. |
| PubMedID- 24743202 | Bisphosphonates(bps)have been widely used for the treatment of hypercalcemia associated with cancer, multiple myeloma bone diseases, and bone metastasis of solid cancers. |
Page: 1